MDT$97.66
$97.77
Chart
Performance
Key Stats
AI MDT Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyMedtronic exhibits strong fundamental health and steady performance, with a growing dividend making it attractive for income-focused investors. While current technicals suggest a neutral short-term outlook, the company's long-term prospects in the medical device sector remain robust.
Thematic
Medtronic is a diversified medical technology company benefiting from global healthcare spending, an aging population, and advancements in medical devices. Its focus on chronic disease management and minimally invasive procedures aligns with key healthcare trends.
Fundamental
Medtronic demonstrates solid financial health with consistent revenue generation and profitability. Its strong balance sheet and growing free cash flow support its dividend payments and strategic investments.
Technical
The stock is trading near its 52-week high, supported by moving averages, but momentum indicators suggest it might be consolidating. A period of sideways movement or a slight pullback could occur before the next significant price move.
| Factor | Score |
|---|---|
| Aging Population | 85 |
| Healthcare Technology Adoption | 75 |
| Chronic Disease Management | 80 |
| Minimally Invasive Procedures | 70 |
| Regulatory Landscape | 60 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 75 |
| Growth | 65 |
| Balance Sheet Health | 75 |
| Cash Flow | 85 |
| Dividend | 90 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 50 |
| Volume | 70 |
| Support & Resistance | 60 |
| Short-Term Indicators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Consistent EPS Beat
Medtronic plc (MDT) has consistently exceeded earnings per share (EPS) estimates, with reported EPS being higher than estimated EPS in the last 12 reported quarters, indicating operational efficiency and strong earnings power.
Reasonable Valuation Metrics
The trailing Price-to-Earnings (P/E) ratio of 25.57 is comparable to the industry average, and the Price-to-Sales (P/S) ratio of 3.5 suggests a reasonable valuation given its revenue generation capabilities.
Bearish Points (8)
Potential Overvaluation based on Quarterly P/E
The latest quarterly P/E ratio of 102.8 (2025Q2) is significantly higher than the trailing annual P/E of 25.57, suggesting that the market might be pricing in very high future growth expectations that could be difficult to meet.
Slowing Quarterly Revenue Growth
While annual revenue has shown growth, the quarterly revenue for 2025Q2 was $8.927 billion, with a net margin of 11.8%. This follows a pattern of fluctuating quarterly performance, with 2024Q2 showing a lower net margin of 7.6% despite higher revenue ($8.589 billion), indicating potential pressure on profitability.
Calendar
June 2025
27
Ex-Dividend Date
July 2025
11
Next Dividend Date
August 2025
19
Next Earnings Date
H: $1.24
A: $1.23
L: $1.22
H: 8.48B
A: 8.37B
L: 8.32B
Profile
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Seasonals
Price Target
97.21 USD
The 39 analysts offering 1 year price forecasts for MDT have a max estimate of 112.45 and a min estimate of 78.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor across multiple core Medtronic segments including cardiovascular (stents, heart failure devices, EP), diabetes (FreeStyle Libre), and diagnostics. They constantly vie for market share.
Weight: 90
Broad healthcare conglomerate with significant medical device segments including Ethicon (surgical technologies) and DePuy Synthes (orthopedics, spine, neuro), which are direct competitors to Medtronic's surgical and restorative therapies groups.
Weight: 90
Major direct competitor in cardiovascular (electrophysiology, structural heart, peripheral interventions), urology, and neuromodulation, directly overlapping with several of Medtronic's key franchises.
Weight: 88
Strong competitor in orthopedics (implants, joint replacement), medical surgical (endoscopy, instruments, navigation), and neurotechnology, areas where Medtronic also has a significant presence.